Generic Lipitor tips Ranbaxy over $2bn revenue mark, but DoJ rap causes loss
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has emerged as the first drug firm of Indian origin to scale the $2 billion sales mark, despite its long-running issues with the US FDA, backed by what appears to be an encouraging start with its generic version of Lipitor (atorvastatin) in the US market.